Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by analysts at Lucid Cap Mkts from a "hold" rating to a "strong-buy" rating.
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights [Yahoo! Finance]
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights